Aptevo Therapeutics Inc
APVO4.720USD
+0.020+0.43%
Fechamento 05/30, 16:00（ET）Cotações atrasadas em 15 min
6.88MValor de mercado
PerdaP/L TTM
Mais detalhes de Aptevo Therapeutics Inc Empresa
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Informações da empresa
Código da empresaAPVO
Nome da EmpresaAptevo Therapeutics Inc
Data de listagemJul 20, 2016
Fundado em2016
CEOMr. Marvin L. White
Número de funcionários37
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 20
Endereço2401 4th Ave Ste 1050
CidadeSEATTLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal98121-3460
Telefone12068380500
Sitehttps://aptevotherapeutics.com/
Código da empresaAPVO
Data de listagemJul 20, 2016
Fundado em2016
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Ms. Daphne L. Taylor
Ms. Daphne L. Taylor
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Daniel J. Abdun-Nabi, J.D.
Mr. Daniel J. Abdun-Nabi, J.D.
Independent Director
Independent Director
--
--
Mr. Grady Grant, III
Mr. Grady Grant, III
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Director
Independent Director
7.00
--
Ms. Barbara Lopez Kunz
Ms. Barbara Lopez Kunz
Independent Director
Independent Director
5.00
--
Dr. John E. Niederhuber, M.D.
Dr. John E. Niederhuber, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.00
--
Mr. Marvin L. White
Mr. Marvin L. White
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.00
+50.00%
Mr. Jeffrey G. Lamothe
Mr. Jeffrey G. Lamothe
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
2.00
--
Ms. So Young Kwon
Ms. So Young Kwon
Senior Vice President, General Counsel, Business Development and Corporate Affairs
Senior Vice President, General Counsel, Business Development and Corporate Affairs
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: qua, 28 de mai
Tempo de atualização: qua, 28 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Estatísticas dos acionistas
Acionista
Proporção
L1 Capital Global Opportunities Master Fund Ltd.
3.11%
Bigger Capital Funds, LP
1.48%
Heights Capital Management, Inc.
1.48%
Geode Capital Management, L.L.C.
0.08%
Schiketanz Capital Advisors GmbH
0.04%
Other
93.81%
Tipo
Acionista
Proporção
Corporation
3.11%
Investment Advisor
1.52%
Hedge Fund
1.50%
Investment Advisor/Hedge Fund
0.08%
Research Firm
0.04%
Other
93.75%
Participação acionária institucional
Tempo de atualização: seg, 24 de fev
Tempo de atualização: seg, 24 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
49
55.12K
0.94%
-14.63K
2024Q4
49
48.74K
3.37%
-20.87K
2024Q3
46
34.83K
7.56%
-18.81K
2024Q2
48
53.21K
48.29%
+52.02K
2024Q1
49
188.00
1.03%
-1.27K
2023Q4
51
1.27K
10.69%
-1.06K
2023Q3
56
2.18K
24.99%
+1.07K
2023Q2
60
629.00
13.58%
-1.76K
2023Q1
67
602.00
13.71%
-1.90K
2022Q4
74
629.00
16.12%
-1.81K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tower Research Capital LLC
1.09K
0.03%
+408.00
+60.18%
Dec 31, 2024
SBI Securities Co., Ltd.
131.00
0%
+131.00
--
Dec 31, 2024
The Vanguard Group, Inc.
56.00
0%
--
--
Jan 31, 2025
Ver Mais
ETFs Relacionados
Tempo de atualização: ter, 6 de mai
Tempo de atualização: ter, 6 de mai
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Data
Tipo
Proporção
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Nov 29, 2024
Merger
37<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 04, 2024
Merger
44<1
Mar 26, 2020
Merger
14<1
Mar 26, 2020
Merger
14<1
Ver Mais
